Real-world use of telavancin in the treatment of osteomyelitis.

[1]  A. Briggs,et al.  Oral versus Intravenous Antibiotics for Bone and Joint Infection , 2019, The New England journal of medicine.

[2]  J. Carton,et al.  Factors predictive of relapse in adult bacterial osteomyelitis of long bones. , 2018, BMC Infectious Diseases.

[3]  T. Wiemken,et al.  Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections. , 2017, Diagnostic microbiology and infectious disease.

[4]  W. Kamysz,et al.  Increasing rate of daptomycin non-susceptible strains of Staphylococcus aureus in patients with atopic dermatitis , 2017, Postepy dermatologii i alergologii.

[5]  S. Cosgrove,et al.  Trends in Methicillin-Resistant Staphylococcus aureus Hospitalizations in the United States, 2010-2014 , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  R. Prokesch,et al.  Outpatient treatment of osteomyelitis with telavancin. , 2017, International journal of antimicrobial agents.

[7]  F. DeLeo,et al.  Vancomycin Resistance in Staphylococcus aureus
 , 2017, The Yale journal of biology and medicine.

[8]  J. Karlowsky,et al.  Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Xiaoling Ma,et al.  Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates , 2015, PloS one.

[10]  T. Wiemken,et al.  Clinical outcomes of osteomyelitis patients infected with methicillin-resistant Staphylococcus aureus USA-300 strains. , 2012, American journal of orthopedics.

[11]  M. Gelfand,et al.  Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. , 2011, The Journal of antimicrobial chemotherapy.

[12]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Niederman,et al.  Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Calhoun,et al.  Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. , 2008, The Journal of antimicrobial chemotherapy.

[15]  V. Fowler,et al.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  K. Rolston,et al.  Cubicin Outcomes Registry and Experience (CORE) methodology. , 2007, The American journal of medicine.

[17]  L. Friedrich,et al.  Clinical experience with daptomycin for the treatment of patients with osteomyelitis. , 2007, The American journal of medicine.

[18]  R. Finch,et al.  Telavancin: in vitro activity against staphylococci in a biofilm model. , 2005, The Journal of antimicrobial chemotherapy.

[19]  Deborah L. Higgins,et al.  Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[20]  F. Waldvogel,et al.  Osteomyelitis , 2004, The Lancet.